title: Neuropeptide Y receptors: a promising target for cancer imaging and therapy.
abstract: Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y1, Y2, Y4 and Y5). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
authors.affiliation: Key Laboratory of Magnetic Materials and Devices & Division of Functional Materials and Nano Devices, Ningbo Institute of Materials Technology & Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.affiliation: Key Laboratory of Magnetic Materials and Devices & Division of Functional Materials and Nano Devices, Ningbo Institute of Materials Technology & Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
authors.forename: Yuchen
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Key Laboratory of Magnetic Materials and Devices & Division of Functional Materials and Nano Devices, Ningbo Institute of Materials Technology & Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
authors.forename: Aiguo
authors.initials: A
authors.lastname: Wu
keywords: cancers; imaging; neuropeptide Y receptors; therapy
references.citation: J Biol Rhythms. 1996 Jun;11(2):145-62
references.pmid: 8744242
references.citation: Neuropeptides. 2010 Jun;44(3):261-8
references.pmid: 20116098
references.citation: J Biol Chem. 2002 Feb 22;277(8):6645-55
references.pmid: 11741903
references.citation: Nature. 1982 Apr 15;296(5858):659-60
references.pmid: 6896083
references.citation: J Neuropathol Exp Neurol. 2008 Aug;67(8):741-9
references.pmid: 18648328
references.citation: Front Endocrinol (Lausanne). 2013 Feb 04;4:5
references.pmid: 23382728
references.citation: Bioorg Med Chem Lett. 2013 Feb 1;23(3):687-92
references.pmid: 23265893
references.citation: Anticancer Agents Med Chem. 2008 Feb;8(2):186-99
references.pmid: 18288921
references.citation: J Med Chem. 2001 May 10;44(10):1479-82
references.pmid: 11334558
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8426-33
references.pmid: 15623622
references.citation: Eur J Pharmacol. 2010 Feb 10;627(1-3):258-64
references.pmid: 19818748
references.citation: Eur J Neurosci. 1997 Jun;9(6):1212-25
references.pmid: 9215705
references.citation: Am J Surg. 2002 Apr;183(4):430-4
references.pmid: 11975932
references.citation: J Med Chem. 1995 Mar 31;38(7):1150-7
references.pmid: 7707318
references.citation: Cancer Res. 2001 Jun 1;61(11):4636-41
references.pmid: 11389101
references.citation: J Clin Invest. 2002 Apr;109(7):915-21
references.pmid: 11927618
references.citation: Cell Signal. 2008 Oct;20(10):1740-9
references.pmid: 18598760
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5043-9
references.pmid: 18698022
references.citation: ChemMedChem. 2015 Jan;10(1):164-72
references.pmid: 25338544
references.citation: J Pept Sci. 2015 Mar;21(3):186-200
references.pmid: 25703117
references.citation: ACS Appl Mater Interfaces. 2015 Mar 11;7(9):5574-82
references.pmid: 25695533
references.citation: Br J Pharmacol. 2003 Jun;139(4):695-704
references.pmid: 12812992
references.citation: Eur J Biochem. 2000 Sep;267(17):5631-7
references.pmid: 10951224
references.citation: J Pept Sci. 2000 Mar;6(3):97-122
references.pmid: 10759209
references.citation: Ann N Y Acad Sci. 1990;611:35-47
references.pmid: 2174222
references.citation: Bioconjug Chem. 2008 Jul;19(7):1430-8
references.pmid: 18572959
references.citation: J Pept Sci. 2009 Dec;15(12):856-66
references.pmid: 19890892
references.citation: Eur J Pharmacol. 2003 Aug 1;474(1):31-42
references.pmid: 12909193
references.citation: Nature. 1996 Jul 11;382(6587):168-71
references.pmid: 8700207
references.citation: Bioconjug Chem. 2001 Nov-Dec;12 (6):1028-34
references.pmid: 11716696
references.citation: Neuropeptides. 2004 Aug;38(4):213-24
references.pmid: 15337373
references.citation: Brain Res. 1993 Dec 17;631(1):27-38
references.pmid: 8298993
references.citation: Mol Pharm. 2015 Apr 6;12(4):1121-30
references.pmid: 25748228
references.citation: Circ Res. 1998 Jul 27;83(2):187-95
references.pmid: 9686758
references.citation: Peptides. 2002 Oct;23(10):1765-71
references.pmid: 12383864
references.citation: Eur J Biochem. 2001 Feb;268(4):877-86
references.pmid: 11179953
references.citation: Virchows Arch. 1999 Dec;435(6):580-9
references.pmid: 10628800
references.citation: Peptides. 2007 Feb;28(2):419-25
references.pmid: 17223228
references.citation: Endocrinology. 2006 Mar;147(3):1466-73
references.pmid: 16339211
references.citation: Adv Drug Deliv Rev. 2014 Jul;74:2-11
references.pmid: 23994441
references.citation: Proc Natl Acad Sci U S A. 1988 May;85(10):3633-7
references.pmid: 2453065
references.citation: J Biol Chem. 1996 Nov 1;271(44):27217-20
references.pmid: 8910290
references.citation: Neuropeptides. 2009 Dec;43(6):491-7
references.pmid: 19781771
references.citation: Bioorg Med Chem Lett. 2010 Feb 1;20(3):950-3
references.pmid: 20042335
references.citation: FEBS J. 2006 May;273(9):2048-63
references.pmid: 16640567
references.citation: Lab Invest. 2004 Jan;84(1):71-80
references.pmid: 14631382
references.citation: J Biol Chem. 1995 Nov 10;270(45):26762-5
references.pmid: 7592911
references.citation: J Biol Chem. 2010 Dec 31;285(53):41578-90
references.pmid: 20959467
references.citation: Neuroreport. 1996 May 17;7(7):1315-9
references.pmid: 8817557
references.citation: Mol Cell Endocrinol. 2011 Apr 30;337(1-2):62-70
references.pmid: 21295110
references.citation: Eur J Biochem. 2001 May;268(10):2828-37
references.pmid: 11358498
references.citation: Domest Anim Endocrinol. 2008 Jul;35(1):24-34
references.pmid: 18325722
references.citation: Int J Cancer. 2005 Jul 10;115(5):734-41
references.pmid: 15704095
references.citation: Regul Pept. 2002 Jul 15;107(1-3):49-62
references.pmid: 12137966
references.citation: ChemMedChem. 2015 May;10 (5):804-14
references.pmid: 25914147
references.citation: Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):803-10
references.pmid: 14985869
references.citation: Cell Mol Life Sci. 2003 Feb;60(2):350-77
references.pmid: 12678499
references.citation: Eur J Pharmacol. 1994 Dec 27;271(2-3):R11-3
references.pmid: 7705422
references.citation: Angew Chem Int Ed Engl. 2010 Feb 1;49(6):1155-8
references.pmid: 20104470
references.citation: Peptides. 1999 Dec;20(12):1445-8
references.pmid: 10698120
references.citation: Can J Physiol Pharmacol. 2000 Feb;78(2):116-25
references.pmid: 10737674
references.citation: Peptides. 1989 Sep-Oct;10(5):963-6
references.pmid: 2558366
references.citation: J Biol Chem. 1995 Dec 8;270(49):29123-8
references.pmid: 7493937
references.citation: J Neurosci. 1998 Apr 15;18(8):3014-22
references.pmid: 9526018
references.citation: Eur J Pharmacol. 1998 May 15;349(1):97-105
references.pmid: 9669502